<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4292568</article-id><article-id pub-id-type="publisher-id">2051-1426-2-S3-P263</article-id><article-id pub-id-type="doi">10.1186/2051-1426-2-S3-P263</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Andtbacka</surname><given-names>Robert HI</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Collichio</surname><given-names>Frances A</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Amatruda</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Senzer</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Chesney</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Delman</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Spitler</surname><given-names>Lynn</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Puzanov</surname><given-names>Igor</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Agarwala</surname><given-names>Sanjiv</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Milhem</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Harrington</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Middleton</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Li</surname><given-names>Ai</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Shilkrut</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Coffin</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Kaufman</surname><given-names>Howard</given-names></name><xref ref-type="aff" rid="I15">15</xref></contrib></contrib-group><aff id="I1"><label>1</label>Huntsman Cancer Institute, Salt Lake City, UT, USA</aff><aff id="I2"><label>2</label>The University of Carolina at Chapel Hill, Chapel Hill, NC, USA</aff><aff id="I3"><label>3</label>Minnesota Oncology, MN, USA</aff><aff id="I4"><label>4</label>Mary Crowley Cancer Research Center, TX, USA</aff><aff id="I5"><label>5</label>University of Louisville, Louisville, KY, USA</aff><aff id="I6"><label>6</label>Emory University, Atlanta, GA, USA</aff><aff id="I7"><label>7</label>Northern California Melanoma Center, San Francisco, CA, USA</aff><aff id="I8"><label>8</label>Vanderbilt University Medical Center, Nashville, TN, USA</aff><aff id="I9"><label>9</label>St. Luke's University Hospital &#x00026; Health Network, Bethlehem, PA, USA</aff><aff id="I10"><label>10</label>University of Iowa, Iowa City, IA, USA</aff><aff id="I11"><label>11</label>The Institute of Cancer Research/The Royal Marsden Hospital, London, UK</aff><aff id="I12"><label>12</label>National Institute for Health Research Biomedical Research Centre, London, UK</aff><aff id="I13"><label>13</label>Amgen Inc, Thousand Oaks, CA, USA</aff><aff id="I14"><label>14</label>Amgen, Woburn, MA, USA</aff><aff id="I15"><label>15</label>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2014</year></pub-date><volume>2</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">Abstracts of the 29th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC)</named-content></supplement><fpage>P263</fpage><lpage>P263</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 I. Andtbacka et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>I. Andtbacka et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/2/S3/P263"/><conference><conf-date>6-9 November 2014</conf-date><conf-name>Society for Immunotherapy of Cancer 29th Annual Meeting</conf-name></conference></article-meta></front><body><sec><title>Background</title><p>T-VEC is an oncolytic immunotherapy derived from herpes simplex virus type-1 designed to selectively replicate within tumors and to produce GM-CSF to enhance systemic antitumor immune responses. OPTiM, a randomized Phase III trial of T-VEC vs GM-CSF in patients with unresected melanoma with regional or distant metastases met the primary objective of an improvement in durable response rate (response lasting continuously for &#x02265;6 months) with T-VEC versus GM-CSF (16% vs 2%, respectively; <italic>P</italic>&#x0003c;0.001). Most common adverse events with T-VEC were fatigue, chills, and pyrexia. No &#x02265;grade 3 adverse events occurred in &#x02265;3% of patients in either arm (Andtbacka et al., <italic>J Clin Oncol </italic>2013,32[suppl]:LBA9008). At the primary analysis (PA) of secondary OS endpoint, with median follow-up of 44 (range, 32-59) months and 189 events in the T-VEC arm and 101 events in the GM-CSF arm, median (95%CI) OS was 23.3 (19.5-29.6) months for T-VEC and 18.9 (16.0-23.7) months for GM-CSF (hazard ratio [HR]=0.79; 95%CI = 0.62-1.00; <italic>P </italic>= 0.051) (Kaufman et al., <italic>J Clin Oncol </italic>2014,32[suppl]:9008a). A planned analysis of OS at 3 years from the last randomization is presented here.</p></sec><sec sec-type="methods"><title>Methods</title><p>Eligible patients were &#x02265;18 years old; had ECOG performance status (PS) &#x02264;1; unresectable melanoma stage IIIB/C/IV; injectable cutaneous, subcutaneous (SC) or nodal lesions; LDH&#x02264;1.5X upper limit of normal; &#x02264;3 visceral lesions (excluding lung), none&#x0003e;3 cm. Patients were randomized 2:1 to intralesional T-VEC (initially &#x02264;4 mL x10<sup>6 </sup>pfu/mL, then after 3 wks, &#x02264;4 mL x10<sup>8 </sup>pfu/mL q2w) or SC GM-CSF (125 &#x000b5;g/m<sup>2</sup>qd &#x000d7; 14 ds q4w).</p></sec><sec sec-type="results"><title>Results</title><p>Of 436 patients in the intent-to-treat analysis, 295 (68%) patients received T-VEC and 141 (32%) patients received GM-CSF; 57% were men; median age 63 yrs. At time of the final OS analysis with median follow-up of 49 months [range, 37-63], only 1 additional event occurred (T-VEC arm). Median (95%CI) OS was 23.3 months (95%CI = 19.5-29.6) for T-VEC and 18.9 months (16.0-23.8) for GM-CSF; HR = 0.80 (95%CI = 0.62-1.01), <italic>P </italic>= 0.06 (descriptive). Five-year survival for the T-VEC arm was 33.4% (95%CI = 27.7-39.2). T-VEC effect on OS was most pronounced in patients with stage IIIB/C/IVM1a melanoma (HR = 0.57; 95%CI = 0.41-0.81, <italic>P </italic>= 0.001 [descriptive]) and in patients with treatment-naive disease (HR = 0.52; 95%CI = 0.36-0.75, <italic>P </italic>&#x0003c; 0.001 [descriptive]).</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>With &#x0003e;4 years of median follow-up for survival, a persistent relevant OS effect was demonstrated with further follow-up. Long-term follow-up continues in the registry trial (NCT02173171). T-VEC represents a novel potential therapy for patients with regionally and distantly metastatic melanoma.</p></sec></body></article>